Antisense oligonucleotides-mediated MDM4 exon 6 skipping could prove useful as a therapeutic strategy for breast carcinoma, melanoma, and diffuse large B cell lymphoma (DLBCL), by decreasing MDM4 abundance and reducing the growth of these tumors [63]. Here, MDM4 is linked to melanoma.